Shenqi compound ameliorates type-2 diabetes mellitus by modulating the gut microbiota and metabolites
- PMID: 35219959
- DOI: 10.1016/j.jchromb.2022.123189
Shenqi compound ameliorates type-2 diabetes mellitus by modulating the gut microbiota and metabolites
Abstract
The gut microbiota (GM) and metabolites are important factors in mediating the development of type-2 diabetes mellitus (T2DM). An imbalance in the gut microbiota and metabolites can disrupt the function of the intestinal barrier, cause changes in the permeability of the intestinal mucosa and promote the immune inflammatory response, thereby aggravating the fluctuation of blood glucose level and promoting the occurrence and development of the chronic complications of DM. Manipulating the GM and metabolites is a promising therapeutic intervention and is being studied extensively. Shenqi compound (SQC) is a traditional Chinese medicine formulation, which has been widely used to improve T2DM. Studies have demonstrated that SQC can reduce glycemic variability, alleviate the inflammatory response, etc. However, its underlying mechanism remains unknown. Therefore, in this experiment, We administered SQC to Goto-Kakizaki (GK) rats and evaluated its effect on blood glucose homeostasis and the intestinal mucosal barrier. We identified the profiles of the GM and metabolites with the aid of 16S rDNA gene sequencing and non-target metabolomics analysis. It showed that SQC intervention could reduce glycemic variability, regulate serum levels of glucagon and insulin, and improve injury to the intestinal mucosal barrier of GK rats. In the gut, the ratio of bacteria of the phyla Bacteroidetes/Firmicutes could be improved after SQC intervention. SQC also regulated the relative abundance of Prevotellaceae, Butyricimonas, Bacteroides, Blautia, Roseburia, Lactobacillus, and Rothia. We found out that expression of 40 metabolites was significantly improved after SQC intervention. Further analyses of metabolic pathways indicated that the therapeutic effect of SQC might be related predominantly to its ability to improve gluconeogenesis/glycolysis, amino acid metabolism, lipid metabolism, citrate cycle, and butanoate metabolism. These results suggest that SQC may exert a beneficial role in T2DM by modulating the GM and metabolites in different pathways.
Keywords: Glycemic variability; Gut microbiota; Intestinal mucosal barrier; Metabolites; Shenqi compound; Type 2 diabetes mellitus.
Copyright © 2022 Elsevier B.V. All rights reserved.
Similar articles
-
Exploration of the Effect and Mechanism of ShenQi Compound in a Spontaneous Diabetic Rat Model.Endocr Metab Immune Disord Drug Targets. 2019;19(5):622-631. doi: 10.2174/1871530319666190225113859. Endocr Metab Immune Disord Drug Targets. 2019. PMID: 30799801
-
Structural Alteration of Gut Microbiota during the Amelioration of Human Type 2 Diabetes with Hyperlipidemia by Metformin and a Traditional Chinese Herbal Formula: a Multicenter, Randomized, Open Label Clinical Trial.mBio. 2018 May 22;9(3):e02392-17. doi: 10.1128/mBio.02392-17. mBio. 2018. PMID: 29789365 Free PMC article. Clinical Trial.
-
An Integrated Fecal Microbiome and Metabolomics in T2DM Rats Reveal Antidiabetes Effects from Host-Microbial Metabolic Axis of EtOAc Extract from Sophora flavescens.Oxid Med Cell Longev. 2020 May 27;2020:1805418. doi: 10.1155/2020/1805418. eCollection 2020. Oxid Med Cell Longev. 2020. PMID: 32566075 Free PMC article.
-
Effect of traditional Chinese medicine on gut microbiota in adults with type 2 diabetes: A systematic review and meta-analysis.Phytomedicine. 2021 Jul 15;88:153455. doi: 10.1016/j.phymed.2020.153455. Epub 2020 Dec 30. Phytomedicine. 2021. PMID: 33478831
-
Modulating the Gut Microbiota and Metabolites with Traditional Chinese Medicines: An Emerging Therapy for Type 2 Diabetes Mellitus and Its Complications.Molecules. 2024 Jun 9;29(12):2747. doi: 10.3390/molecules29122747. Molecules. 2024. PMID: 38930814 Free PMC article. Review.
Cited by
-
Review of the correlation between Chinese medicine and intestinal microbiota on the efficacy of diabetes mellitus.Front Endocrinol (Lausanne). 2023 Jan 25;13:1085092. doi: 10.3389/fendo.2022.1085092. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36760813 Free PMC article. Review.
-
Investigation of the hypoglycemic mechanism of the ShenQi compound formula through metabonomics and 16S rRNA sequencing.Front Pharmacol. 2024 Apr 19;15:1349244. doi: 10.3389/fphar.2024.1349244. eCollection 2024. Front Pharmacol. 2024. PMID: 38708085 Free PMC article.
-
Novel mechanisms of intestinal flora regulation in high-altitude hypoxia.Heliyon. 2024 Sep 20;10(20):e38220. doi: 10.1016/j.heliyon.2024.e38220. eCollection 2024 Oct 30. Heliyon. 2024. PMID: 39498080 Free PMC article.
-
Pharmacomicrobiomics and type 2 diabetes mellitus: A novel perspective towards possible treatment.Front Endocrinol (Lausanne). 2023 Mar 23;14:1149256. doi: 10.3389/fendo.2023.1149256. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37033254 Free PMC article. Review.
-
Evidence of traditional Chinese medicine for treating type 2 diabetes mellitus: from molecular mechanisms to clinical efficacy.Pharm Biol. 2024 Dec;62(1):592-606. doi: 10.1080/13880209.2024.2374794. Epub 2024 Jul 19. Pharm Biol. 2024. PMID: 39028269 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical